ADAPTIVEMOBILE-SECURITY
12.9.2019 09:09:08 CEST | Business Wire | Press release
Following extensive research, AdaptiveMobile Security, a world leader in cyber-telecoms security, today announced it has uncovered a new and previously undetected vulnerability. This vulnerability is currently being exploited and is being used for targeted surveillance of mobile phone users. The vulnerability and its associated attacks have been named, ‘Simjacker’ as it involves the hijacking of SIM cards and threatens mobile phone users across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005038/en/
Simjacker extracts the location information of mobile phone users from vulnerable operators, retrieved using malicious SMS messages. The location information of thousands of devices was obtained over time without the knowledge or consent of the targeted mobile phone users. Based on previous intelligence, it is likely that these attacks originated from a surveillance company which works with governments, to track and monitor individuals; bypassing existing signalling protection.
Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security explained, “Simjacker represents a clear danger to the mobile operators and subscribers. This is potentially the most sophisticated attack ever seen over core mobile networks. It’s a major wake-up call that shows hostile actors are investing heavily in increasingly complex and creative ways to undermine network security. This compromises the security and trust of customers, mobile operators and impacts the national security of entire countries.”
While the primary attack detected involved the retrieval of mobile phone locations, Simjacker has been further exploited to perform many other types of attacks against individuals and mobile operators such as fraud, scam calls, information leakage, denial of service and espionage. AdaptiveMobile Security Threat Intelligence analysts observed the hackers vary their attacks, testing many of these further exploits.
In theory, all makes and models of mobile phone are open to attack as the vulnerability is linked to a technology embedded on SIM cards. AdaptiveMobile Security research indicates that the Simjacker vulnerability could extend to over 1 billion mobile phone users globally, potentially impacting countries in North and South America, West Africa, Europe, Middle East and indeed any region of the world where this SIM card technology is in use.
Mc Daid continued, “Simjacker worked so well and was being successfully exploited for years because it took advantage of a combination of complex interfaces and obscure technologies, showing that mobile operators cannot rely on standard established defences. Now that this vulnerability has been revealed, we fully expect the exploit authors and other malicious actors will try to evolve these attacks into other areas”.
AdaptiveMobile Security has been working closely with their customers and the wider industry; including both mobile network operators and SIM card manufacturers to protect mobile phone subscribers. AdaptiveMobile Security are committed to using their global threat intelligence to build defences against these new sophisticated attacks that are circumventing current security measures.
Further details on Simjacker are available on www.simjacker.com and Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security will be presenting on Simjacker at the Virus Bulletin Conference, London, 3 October 2019.
---Ends---
About
AdaptiveMobile Security is the world leader in cyber-telecoms security, protecting over 2.1 billion subscribers worldwide. The combination of global insight provided by our security specialists teams, our world-leading Threat Intelligence Unit and our proprietary, telecom-grade Network Protection Platform are trusted by the world’s largest service providers to secure their critical communications infrastructure.
The Company HQ is in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
